Antibody Optimization and Engineering Service

Effect of Targeted Antigens on Therapeutic Antibodies

The choice of targeting antigen affects the primary and tertiary structure of the variable region of the antibody, which may affect the nature of the antibody-antigen interaction, potency, and therapeutic index.

Effect of Antibody Types on Therapeutic Antibodies

Similarly, factors such as antibody subclass and isotype affect the structure of the constant region, which in turn affects binding to the Fc receptor, which is critical for effector function and serum half-life.

One-step Antibody Development

Alfa Cytology creates a unique end-to-end antibody discovery and development platform for your therapeutic antibody program. After antibody optimization and engineering, we also provide a series of preclinical research services. Our services cover a wide range of antibody types.

Antibody Humanization

Non-human antibodies have been shown to induce an immune response in humans, leading to neutralization of the administered antibody and limiting the use of such antibodies in the treatment of human diseases. Humanization of antibodies is an effective way to eliminate or reduce the immunogenicity of such antibodies. Alfa Cytology offers human/mouse chimeric antibodies, fully human antibodies, and human antibody recombination to enhance the safety and efficacy of antibodies in therapeutic applications.

Affinity Maturation

Affinity maturation is the process by which antibody affinity, potency, and anti-pathogen activity are enhanced as a result of somatic hypermutation (SHM) of immunoglobulin genes in B cells, as well as antigen-binding selection. Alfa Cytology improves and enhances the affinity of an antibody to bind to its target antigens, through homology library screening, DNA recombination, or point mutation techniques.

Antibody Liability Removal

Reducing the risk of precursors upfront improves developability and minimizes the chances of clinical failure due to poor molecular characterization. Alfa Cytology modulates the motifs present in the final antibody by using a defined collection of natural complementary-determining region (CDR) sequences that lack sequence defects.